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Plasma levels of endothelin-1 (ET-1) and adrenomedullin
(ADM), two opposingly acting peptides, correlate with mortal-
ity in endotoxemia, but their measurement is cumbersome. New
sandwich assays have been introduced that measure more stable
precursor fragments. The objective of this study was to investi-
gate the counterplay of their precursor peptides in septic patients
and to compare them with disease severity and other biomarkers.
Blood samples of an observational study in 95 consecutive criti-
cally ill patients admitted to the intensive care unit (ICU) were
analyzed.CT-proET-1andMR-proADMconcentrationsonadmis-
sion were measured using new sandwich immunoassays. Depend-
ing on the clinical severity of the infection, both CT-proET-1 and
MR-proADMlevelsexhibitedagradualincreasefromSystemicIn-
ﬂammatory Response Syndrome (SIRS) to sepsis and septic shock
(p < .001). Compared to the group of survivors, the group of non-
survivors had higher median values of MR-proADM (5.7 nmol/L
[range 0.4 to 21.0] versus 1.9 nmol/L [range 0.3 to 17.1], p < .02)
andsimilarCT-proET-1levels(56.0pmol/L[range0.5to271.0]ver-
sus 54.1pmol/L [range 1.0 to 506.0], p = .86). Receiver operating
characteristics (ROC) curve analysis showed a higher prognostic
accuracyofthecalculatedratioofbothcounteractingsubstancesas
comparedtoCT-proET-1(p =0.001)andC-reactiveprotein(CRP)
(p = .001) and in the range of MR-proADM (p = .51), procalci-
tonin(p =0.22),andtheAPACHEIIscore(p =.61).Endothelin-1
andadrenomedullinprecursorpeptidesgraduallyincreasewithin-
creasing severities of infection in critically ill patients. The ratio of
thetwocounteractingpeptidescorrelateswithmortalityandshows
ap r ognostic accuracy to predict adverse outcome comparable to
the APACHE II score.
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The main cause of death in patients with sepsis is multi-
ple organ failure and volume refractory hypotension, which are
frequently complicated by impaired tissue perfusion and my-
ocardial depression. Endothelin-1 (ET-1) and adrenomedullin
(ADM), two endothelium-derived vasoactive peptides, have at-
tracted interest as physiological key mediators in vascular tone
regulation in sepsis and cardiovascular disease (Levin 1995;
Hinson et al.2000;Landryetal.2004;Christ-Crainetal.2005).
ET-1, a 21–amino acid peptide, is mainly derived by vascular
endothelialcellsandactsasaverypotentvasoconstrictor(Levin
1995; Tschaikowsky et al. 2000). Conversely, ADM is a potent
vasodilator, which assures blood supply to the individual or-
gan and has been shown to be increased in systemic infections
(Christ-Crain et al. 2005, 2006). Both peptides correlate with
mortality and, thus, have been put forward as prognostic mark-
ers of disease severity in septic syndrome (Ueda et al. 1999;
Brauner et al. 2000). However, the methodological reliability of
plasmaET-1andADMmeasurementsischallengingbecauseof
their rapid clearance from the circulation, limiting their use in
commonpractice(Hinsonetal.2000;Eto2001).Therefore,new
sandwichassayshavebeenintroducedthatmeasurethemoresta-
ble precursor fragments CT-proET-1 and MR-proADM. Unlike
the mature peptides, these fragments can be detected for hours
in the circulation. Because of the stoichiometrical generation,
these “prohormones” represent the release of the active peptide,
a situation similar to that of C-peptide and insulin. Thus, these
fragments can be used to indirectly assess the release of the
mature peptides in physiological and pathological conditions.
To investigate the interaction and a possible predictive value
of the precursor peptides of ET-1 and ADM in sepsis, we
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measured CT-proET-1 and MR-proADM in a previously well-
described cohort of medical intensive care patients and com-
paredthoselevelswithtraditionalbiomarkers,adiseaseseverity
score, and medical outcome.
MATERIAL AND METHODS
Patients
The present study evaluated asserved plasma samples of 95
out of a cohort of 101 consecutive critically ill patients admit-
ted to the medical intensive care unit (ICU) of the University
Hospital of Basel, Switzerland, between September 1996 and
June 1997. The primary end point was the assessment of the
prognostic value of endocrine dysfunctions in critically ill pa-
tients (“PEDCRIP” study). Details of the characteristics of the
study population, study design, the diagnostic criteria, and the
levels of different markers of inﬂammation and infection have
been reported in detail (Muller et al. 2000a, 2000b, 2001, 2002;
Christ-Crain et al. 2005).
Brieﬂy, over a 9-month period, 101 consecutive patients, in-
cluding neutropenic and immunosuppressed patients, admitted
to the medical ICU were included. Patients were followed un-
til hospital discharge or death. Vital signs, clinical status, and
severity of disease were assessed daily and the commonly used
physiologicalAPACHEIIscorewascalculated.Forthepurpose
of this study, only data collected during the ﬁrst 24 h of ad-
mission were assessed. The primary end point was in-hospital
mortality. Pulmonary artery catheter was not routinely inserted.
Whenfeasible,consentwasobtainedpriortoenrollmentincon-
scious patients; otherwise, the consent was obtained from the
patients’ next of kin. The study protocol had prior approval by
the hospital institute ethical review board.
Patients were classiﬁed at the time of blood collection into
sepsis, septic shock and Systemic Inﬂammatory Response Syn-
drome (SIRS) using international, standardized criteria (Bone
et al. 1992). In case of uncertainty of infection, a complete,
retrospective patient chart review including results of microbi-
ological cultures, chest radiographs, and, when available, post-
mortem examination reports, was performed by an infectious
disease specialist. An isolated microorganism was considered
to be pathogenic if recovered within a 24-h period before or
after the onset of the systemic response. Microbiological tests
and antibiotic therapy were prescribed by physicians on duty
according to the usual practice, without interference by the re-
search team.
Assays
Results of the routine blood analyses were recorded. Plasma
onadmissionwascollectedatthetimeofbloodsamplinginplas-
tic tubes containing ethylenediaminetetraacetic acid (EDTA).
They were placed on ice and then centrifuged at 3000 ×g; and
plasma was frozen at −70◦C until assayed. Pro-endothelin-1
fragments (CT-proET-1) and mid-regional pro-adrenomedullin
(MR-proADM) were detected with two new sandwich im-
munoassays (Sevacon LIA and Sevadil LIA, respectively;
B.R.A.H.M.S AG, Hennigsdorf/Berlin, Germany), as described
in detail elsewhere (Christ-Crain et al. 2005; Morgenthaler et
al. 2005; Struck et al. 2005; Papassotiriou et al. 2006). Brieﬂy,
both immunoassays employ two polyclonal antibodies to the
amino acids 168–212 of pre-pro-endothelin-1 and amino acids
45–92 of pre-pro-adrenomedullin MR-proADM (amino acids
45 to 92) and have analytical detection limits of 0.4 and 0.08
nmol/L, respectively. Values for both analytes followed a Gaus-
sian distribution in healthy individuals without signiﬁcant dif-
ferences between males and females (Morgenthaler et al. 2005;
Papassotiriou et al. 2006).
Procalcitonin was measured using LUMITest PCT
(B.R.A.H.M.S AG) with a functional assay sensitivity of
around 0.3 to 0.5 ng/mL. C-reactive protein (CRP) was
measured by an enzyme immunoassay (EMIT; Merck Diag-
nostica, Zurich, Switzerland), where a value of >10 mg/L
was considered to be abnormally elevated. All assays showed
linear dilution, and undisturbed recovery of the analyte after
pooling of samples or addition of synthetic analyte. The lab-
oratory technician who measured CT-proET-1, MR-proADM,
procalcitonin, and CRP was at a different site and blinded to
the characteristics of the patients and the characteristics of the
study.
Statistical Analysis
Frequency comparison was done by chi-square test. Two-
group comparison of not normally distributed data was per-
formed by the Mann-Whitney U test. For multigroup compar-
isons, Kruskal-Wallis one-way analysis of variance with least
squaredifferenceforposthoccomparisonwasused.Correlation
analyses were performed by using Spearman’s rank correlation.
Levels that were nondetectable were assigned a value equal to
the lower limit of detection for the assay. All testing was two-
tailed and p values less than .05 were considered to indicate
statistical signiﬁcance. All calculations including receiver op-
erating characteristics (ROC) were performed using Stata 9.2
(Stata, College Station, TX).
RESULTS
Descriptive Characteristics of the Patients
The mean age of the 95 patients included in this study was
57 (range 23 to 86) years. On admission, the mean APACHE
II score was 21 ± 8 points. The median length of stay in the
medical ICU was 4 days (range 0.2 to 60 days). The diagnoses
onadmissionaresummarizedinTable1.SIRSwithoutinfection
wasdiagnosedin47patients.Sepsiswasdiagnosedin48patients
(including 15 patients with septic shock). The principal site of
infectionwasthelung.Theneedforbloodpressuresupportwith
vasoactivaonadmissionwas28%inpatientswithSIRSand52%
and 80% in patients with sepsis and septic shock, respectively.ENDOTHELIN-1 AND ADRENOMEDULLIN IN SEPSIS 347
TABLE 1
Clinical diagnosis and site of infection






































































48 (50.5) 26 (27.4) 28 (29.5) 13 (13.7) 21 (22.1) 16 (16.8)
∗One patient can have more than one diagnosis. Therefore, the total exceeds the absolute number of patients.
The in-hospital mortality rate of all patients was 22% of the
48 patients admitted with sepsis, 12 died (25%) of multiorgan
failure, whereas 9 out of the 47 patients with SIRS (19%) did
not survive the hospital stay.
FIG. 1. CT-proET-1 and MR-proADM values in all patients according to the severity of disease. Patients’ data on admission to the ICU were grouped according
to the severity of the disease following consensus criteria in groups with “SIRS, but no sepsis,” “sepsis,” and “septic shock.” Squares denote median values and
whiskers indicate 25th and 75th percentiles.
CT-proET-1 and MR-proADM Levels and Severity
of the Disease
Figure 1 shows CT-proET-1 and MR-proADM values of all
95 critically ill patients on admission according to severity of348 P. SCHUETZ ET AL.
disease(SIRS,sepsis,andsepticshock).Dependingontheclini-
cal severity of the infection, MR-proADM and CT-proET-1 lev-
els exhibited a gradual increase from the group with SIRS to
the group with septic shock (p < .001). Patients with SIRS had
median CT-proET-1 levels of 23.1 pmol/L (range 0.5 to 158.0),
patients with sepsis of 64.3 pmol/L (range 2.0 to 271.0), and
patients with septic shock of 131.6 pmol/L (range 3.0 to 506.0).
The respective MR-proADM levels were (range 0.3 to 3.7), 2.6
(range 0.4 to 13.8), and 8.0 (range 0.9 to 21.0) nmol/L. Post hoc
analysisforCT-proET-1andMR-proADMshowedasigniﬁcant
difference between patients with SIRS and patients with sepsis
(p < .01 and p < .001) and for patients with sepsis and patients
with septic shock (p < .05 and p < .003). Baseline CT-proET-1
values of all patients demonstrated a signiﬁcant correlation with
other markers of infection, i.e., procalcitonin (r = .39, p <
.05) and CRP (0.35, p < .05), and with mean blood pressure
(r =− .25, p < .05). Baseline MR-proADM levels of all pa-
tients correlated with procalcitonin (r = .40, p < .05), CRP
(r = .35, p < .05), mean blood pressure (r =− .29, p < .05),
and the APACHE II score (r = .41, p < .05). There was a sig-
niﬁcant correlation between the two peptides CT-proET-1 and
MR-proADM (r = .54, p < .001).
CT-proET-1 and MR-proADM Levels and Outcome
of All Patients
Figure 2 shows CT-proET-1 levels, MR-proADM levels and
thecalculatedratioofbothprecursorpeptides(CT-proET-1/MR-
proADM ratio) of all survivors and nonsurvivors with SIRS,
sepsis, and septic shock on admission. The median CT-proET-1
value in the group of nonsurvivors (54.1 pmol/L [range 1.0 to
506.0]) was not signiﬁcantly different from the group of sur-
vivors (56.0 pmol/L [range 0.5 to 271.0]), p = .87. In con-
trast, nonsurvivors had higher median values of MR-proADM
(5.7 nmol/L [range 0.4 to 21.0] as compared to survivors (1.9
nmol/L [range 0.3 to 17.1]), p < .02. Nonsurvivors had a lower
median CT-proET1/MR-ADM ratio (12.0 [range 0.5 to 44.6])
as compared to survivors (29.0 [range 0.7 to 127.2]), p < .002.
Post hoc analysis of those patients with sepsis and in need
for blood pressure support with vasoactiva (n = 30) showed
higher MR-proADM values (9.6 [range 0.8 to 21.0] versus 3.4
[range 0.55 to 17.1]) and lower CT-proET-1 values (70.9 [range
3.0 to 175.0] versus 93 [range 2.0 to 506]) for surviving pa-
tients (n = 21) as compared to nonsurvivors. The calculated
CT-proET1/MR-proADM ratio was signiﬁcantly lower in non-
survivors(6.8[range0.5to16.5]versus25.7[range2.3to58.2],
p < .01).
To illustrate and compare the predictive value of CT-proET1,
MR-proADM and the calculated ratio of the two peptides of
all 95 critically ill patients with SIRS, sepsis, and septic shock
(Figure 3a) and for all 30 patients with sepsis and in need of
blood pressure support with vasoactiva on admission (Figure
3b), we performed a receiver operating characteristic (ROC)
plot analysis. ROC plots are graphical plots of the sensitivity
FIG. 2. CT-proET-1-, MR-proADM, and the calculated ratio in surviving as
compared to nonsurviving patients. Data from all patients on admission are
shown. Squares denote median values, boxes represent 25th to 75th percentiles
and whiskers indicate the range.
and the speciﬁcity of a binary classiﬁer system for all cut-off
points of a diagnostic or prognostic test and its overall perfor-
mance is expressed as the area under the ROC curve (AUC).
For this analysis, sensitivity was calculated with those patients
who did not survive their disease during the hospital stay and
speciﬁcitywasassessedwiththosepatientswhodidsurvive.For
comparison, the same ROC plot analysis was performed for dif-
ferent prognostic markers, namely procalcitonin, CRP, and the
APACHE II score. ROC analysis for survival of all critically ill
patients revealed AUCs of 0.49 for CT-proET-1, 0.67 for MR-
proADM, 0.73 for the CT-proET-1/MR-proADM ratio, 0.69 for
the APACHE II score, 0.62 for procalcitonin, and 0.58 for CRP.ENDOTHELIN-1 AND ADRENOMEDULLIN IN SEPSIS 349
FIG. 3. Receiver operating curve (ROC) analysis of CT-proET1, MR-
proADM, the CT-proET1/MR-proADM ratio and the APACHE II score with
respect to outcome prediction of critically ill patients. Receiver operating char-
acteristic (ROC) plots are graphical plots illustrating the sensitivity (y-axis) and
the speciﬁcity (x-axis) for all cut-off points of a diagnostic or prognostic test.
The overall performance and a summary measure of the diagnostic accuracy of
a test can be expressed as the area under the ROC curve (AUC). Note that an
AUCo f0.50 means that the diagnostic accuracy in question is equivalent to that
whichwouldbeobtainedbyﬂippingacoin(i.e.,randomchance).(a)Dataofall
patients(n =95)withSIRSandsepsisonadmissiontotheICU.Sensitivitywas
calculated with nonsurvivors (n = 21), speciﬁcity with survivors (n = 74) dur-
ing their hospital stay. (b) Data of patients with sepsis (including septic shock)
in need for blood pressure support with vasoactiva (n = 30) on admission to
the ICU. Sensitivity was calculated with nonsurvivors (n = 9), speciﬁcity with
survivors (n = 21) during their hospital stay.
In patients with sepsis and in need of blood pressure support,
the AUC for the CT-proET-1, MR-proADM, CT-proET-1/MR-
proADM ratio, and the APACHE II score were 0.49, 0.76, 0.81,
and 0.60, respectively.
In all 95 patients, the optimal threshold for the CT-proET-
1/MR-proADM ratio was at 11. At this cut-off, the sensitivity
for the correct prediction of death was 71.4% and the speciﬁcity
was 71.6%. In comparison, the APACHE II score was also pre-
dictive for prognosis but gave lower values for the speciﬁcity
as compared to the ET1/ADM ratio. The prognostic accuracies
and likelihood ratios for the CT-proET1/MR-proADM ratio and
theAPACHEIIscoreatdifferentcut-offsindiagnosingsurvival
are shown in Table 2.
TABLE 2
Sensitivity, speciﬁcity, and likelihood ratios of the APACHE II
score and the calculated CT-proET-1/MR-proADM ratio in
critically ill patients
Sensitivity Speciﬁcity LR + LR −
APACHE II score
>19 81.0 35.1 1.2 0.5
>25 52.4 71.6 1.8 0.7
>36 23.8 98.7 17.6 0.8
ET1/ADM ratio
<3 89.2 19.0 0.4 1.8
<11 71.4 71.6 0.9 2.5
<27 44.6 90.5 0.2 1.6
DISCUSSION
This study found a gradual about eightfold increase of both
endothelium-derived precursor peptides, CT-proET-1 and MR-
proADM, in the plasma of septic patients with increasing sever-
ity of infection. Interestingly, the interplay of the two counter-
acting substances, expressed as the ratio between CT-proET-1
and MR-proADM, correlated with mortality and had a similar
prognostic accuracy as compared to the APACHE II score.
In sepsis, microorganisms entering the bloodstream may re-
lease their toxins, resulting in a host-derived mediator response
activating an inﬂammatory cascade of various peptides. Ac-
cumulating evidence indicates a major role for different va-
soactive substances causing dysregulation of the endothelium
and consecutive collapse of blood pressure and microvascular
homeostasis (Grandel et al. 2003; Peters et al. 2003). The two
endothelium-derived peptides ET-1 and ADM have been sug-
gested as two pivotal mediators in this process of vascular tone
regulation. ADM contributes to the extensive vasodilatation and
hypotension often seen in severe sepsis and especially in septic
shock (Hinson et al. 2000; Struck et al. 2004). Conversely, with
its potent vasoconstrictor properties, the vascular tissue-wide
production of ET-1 counteracts this vasodilatation and hypoten-
sionandthereforeassuresbloodpressurehomeostasisandblood
supply to the individual organs (Kedzierski et al. 2001). Ac-
cordingly, in our study both precursor peptides were markedly
increased in different severities of sepsis and both substances
correlated with mean blood pressure.
Brauner and coworkers demonstrated an association of ET-
1l evels and mortality in septic patients only when measured
6hafter admission (Brauner et al. 2000). Similarly, ADM has
beensuggestedtoserveasanoutcomepredictorinpatientswith
SIRS and sepsis (Ueda et al. 1999; Christ-Crain et al. 2005).
In our study, baseline MR-proADM levels but not ET-1 levels
were signiﬁcantly higher in patients not surviving their disease
ascomparedtothosewhodid.Apossiblereasonforthedifferent
resultsbetweenourstudyandthestudybyBrauneretal.wasthat
we did not measure the dynamics of these peptides, especially350 P. SCHUETZ ET AL.
ET-1, in the course of disease. However, a biomarker whose
prognostic value is only present at 6 h and not at earlier or later
time points is arguably of minor clinical help.
Inthisstudy,weusedROCcurvescomparingsensitivitiesand
speciﬁcities at any given cut-off point to compare the summary
measure of the prognostic accuracy of the precursor peptides
as compared to the clinical APACHE II score. Interestingly, the
calculated ratio between the potent vasoconstrictor CT-proET-1
and its vasodilating opponent MR-proADM improved the prog-
nostic accuracy to predict mortality as compared to each pep-
tide alone and was similar to the routinely used physiological
APACHEIIscore.Incriticallyillsepticpatients,therisk-beneﬁt
ratio of a speciﬁc therapy might depend on the extent of the dis-
ease severity. For example, only the subgroup of patients with
the highest risk of dying, reﬂected in an APACHE II score of
more than 24 points, is beneﬁting from the administration of
activated protein C (Drotrecogin alpha). The APACHE II score
was originally suggested not to be used for individual outcome
prediction of sepsis patients (Wagner et al. 1984). The use of
the APACHE II score for individual treatment decisions can
be problematic because of the difﬁculties of determining the
score clinically (Abraham et al. 2005; Parrillo 2005). Calculat-
ing clinical scores is time consuming, sometimes complex, and
shows a high interobserver variability (Polderman et al. 2001;
Booth et al. 2005). However, despite its inherent limitations,
outcome predictors are clearly helpful in identifying those sep-
tic patients with a high risk of death, who are more likely to
beneﬁt from intervention treatment. In our opinion, it is ad-
visable to base the difﬁcult task of prognostic assessment and
treatment decisions on several parameters that each mirror dif-
ferent physiological aspects. In this context, upon availability in
the routine setting, determination of the CT-proET-1 and MR-
proADM ratio might prove to be an additional helpful tool for
a broader prognostic classiﬁcation of septic patients. With its
higherspeciﬁcityascomparedtotheAPACHEIIscore,itmight
provide an additional margin of safety. We endorse further stud-
ies to validate our results and to prospectively identify patients
in whom these peptides could possibly improve the APACHE II
score.
ET-1 originates from a larger precursor peptide, which is
ﬁrst proteolytically processed to big ET-1 and further excised
by the action of endothelin-converting enzyme (Rongen et al.
1994). In this study the precursor fragment of ET-1 was cho-
sen to monitor, because pro-ET-1 fragments can be detected for
hours after its cleavage in the circulation, in contrast to ET-1,
which is eliminated within minutes and therefore escapes de-
tection in clinical routine (Weitzberg et al. 1991). Importantly,
CT-proET-1 fragments are produced in a stoichiometrical ra-
tio to ET-1 and can thus be used to indirectly assess the re-
lease of ET-1 in physiological and pathological conditions. For
the same reasons we measured MR-proADM instead of ma-
ture ADM. The measurement of mature ADM is technically
challenging and the reliable measurement almost impossible,
because it is rapidly cleared from the circulation (Hinson et al.
2000; Eto 2001). Recently, the more stable mid-regional frag-
ment of pro-adrenomedullin (MR-proADM) comprising amino
acids 45 to 92, which directly reﬂects levels of the rapidly de-
graded active peptide ADM, was identiﬁed in the plasma of
patients with septic shock (Struck et al. 2004) and a technically
very robust and reliable assay for this peptide was subsequently
developed.
Our study has limitations. First, as an observational study,
a contamination bias is obvious and we interpret our results as
preliminaryandhypothesisgenerating.Largerstudiesshouldbe
done to conﬁrm the external validity of our ﬁndings. Therefore,
daily measurements of blood values including the CT-proET-
1/MR-proADM ratio and invasive assessment of macro- and
microvascular tone and cardiac function should be preformed.
Second, a single biomarker will always oversimplify the inter-
pretation of important variables and, therefore, the CT-proET-
1/MR-proADM ratio is meant to contribute to, rather than su-
persede, clinician’s judgment and the validated APACHE II
score.
Inconclusion,baselineendothelin-1andadrenomedullinpre-
cursor levels are signiﬁcantly increased in patients with sepsis
andsepticshock.Combiningbothcounteractingpeptidesinara-
tio reﬂecting vasomotor status correlates with mortality in these
patients. With a high speciﬁcity to predict bad outcome, the CT-
proET1/MR-proADM ratio could complement the APACHE II
score.
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